12-Sep-2022
Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum
|
Relief Therapeutics Holding SA
/ Key word(s): Conference
Geneva, Switzerland, September 12, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), a Swiss, commercial-stage biopharmaceutical company seeking to provide patients therapeutic benefit from selected specialty, rare and ultra-rare diseases with high unmet need, today announced that Jack Weinstein, Chief Financial Officer and Treasurer, will participate in a panel discussion and present a company overview during the 22nd Annual Biotech in Europe Forum, being held September 21-22, 2022, in Basel, Switzerland. Panel Discussion Title: Navigating Global Capital Markets in Current Times Date: Wednesday, September 21, 2022 Time: 1:35 pm CEST Company Presentation Date: Wednesday, September 21, 2022 Time: 3:20 pm CEST Management will host one-on-one meetings during the event. Institutional investors and others, who are registered for the conference, can log into https://sachsevent.com/event/22nd-bef/about to request a meeting with the company. ABOUT RELIEF Relief is a Swiss, commercial-stage, biopharmaceutical company focused on identification, development and commercialization of novel, patent protected products intended for the treatment of rare and ultra-rare diseases including metabolic disorders, pulmonary diseases and connective tissue disorders. Relief’s diversified pipeline consists of assets that have the potential to effectively address significant unmet medical needs, including PKU GOLIKE®, engineered with the proprietary Physiomimic technology, which is the first prolonged-release amino acid product commercialized for the dietary management of phenylketonuria ("PKU"). Relief has a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including Urea Cycle Disorders (“UCDs”) and Maple Syrup Urine Disease (MSUD). Relief also continues to develop aviptadil for several rare pulmonary indications. Relief is in clinical development for APR-TD011, a differentiated acid oxidizing solution of hypochlorous acid intended for the treatment of epidermolysis bullosa ("EB"), a group of rare, genetic, life-threatening connective tissue disorders; APR-TD011 has been granted Orphan Drug Designation by the FDA. In addition, Relief is commercializing several legacy products via licensing and distribution partners. RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com. Follow Relief on LinkedIn.
Additional features: File: Press release
End of Media Release |
| Language: | English |
| Company: | Relief Therapeutics Holding SA |
| Avenue de Secheron 15 | |
| 1202 Geneva | |
| Switzerland | |
| Phone: | +41 22 545 11 16 |
| E-mail: | contact@relieftherapeutics.com |
| Internet: | https://relieftherapeutics.com |
| ISIN: | CH0100191136 |
| Valor: | 10019113 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1439731 |
| End of News | EQS News Service |
Editor Details
-
Company:
- EQS Newsfeed
- Website:
Last Updated: 12-Sep-2022
